Alcohol Stimulates Macrophage Activation Through Caspase-dependent Hepatocyte Derived Release of CD40L Containing Extracellular Vesicles

Overview

Journal J Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2015 Dec 4

PMID 26632633

Citations 131

Authors

Vikas K Verma

Haiyang Li

Ruisi Wang

Petra Hirsova

Malek Mushref

Yaming Liu

Sheng Cao

Patricia C Contreras

Harmeet Malhi

Patrick S Kamath

Gregory J Gores

Vijay H Shah

Affiliations

Soon will be listed here.

Abstract

Background & Aims: The mechanisms by which hepatocyte exposure to alcohol activates inflammatory cells such as macrophages in alcoholic liver disease (ALD) are unclear. The role of released nano-sized membrane vesicles, termed extracellular vesicles (EV), in cell-to-cell communication has become increasingly recognized. We tested the hypothesis that hepatocytes exposed to alcohol may increase EV release to elicit macrophage activation.

Methods: Primary hepatocytes or HepG2 hepatocyte cell lines overexpressing ethanol-metabolizing enzymes alcohol dehydrogenase (HepG2(ADH)) or cytochrome P450 2E1 (HepG2(Cyp2E1)) were treated with ethanol and EV release was quantified with nanoparticle tracking analysis. EV mediated macrophage activation was monitored by analysing inflammatory cytokines and macrophage associated mRNA expression, immunohistochemistry, biochemical serum alanine aminotransferase and triglycerides analysis in our in vitro macrophage activation and in vivo murine ethanol feeding studies.

Results: Ethanol significantly increased EV release by 3.3-fold from HepG2(Cyp2E1) cells and was associated with activation of caspase-3. Blockade of caspase activation with pharmacological or genetic approaches abrogated alcohol-induced EV release. EV stimulated macrophage activation and inflammatory cytokine induction. An unbiased microarray-based approach and antibody neutralization experiments demonstrated a critical role of CD40 ligand (CD40L) in EV mediated macrophage activation. In vivo, wild-type mice receiving a pan-caspase, Rho kinase inhibitor or with genetic deletion of CD40 (CD40(-/-)) or the caspase-activating TRAIL receptor (TR(-/-)), were protected from alcohol-induced injury and associated macrophage infiltration. Moreover, serum from patients with alcoholic hepatitis showed increased levels of CD40L enriched EV.

Conclusion: In conclusion, hepatocytes release CD40L containing EV in a caspase-dependent manner in response to alcohol exposure which promotes macrophage activation, contributing to inflammation in ALD.

Citing Articles

Therapeutic Actions of Hepatocyte Extracellular Vesicles in a Murine Model of Diet-Induced Steatohepatitis with Fibrosis.

Li X, Chen R, Kemper S, Xu Z, Brigstock D Biomedicines. 2025; 13(2).

PMID: 40002688 PMC: 11852249. DOI: 10.3390/biomedicines13020274.

MicroRNA Expression Profile in the Patient's Plasma Exosomes of Alcohol-Induced Osteonecrosis of Femoral Head: Potential Vascular Regulation Mechanism.

Chen W, Li C, Yi Z, Luo G, Zhang P, Wu P J Cell Mol Med. 2025; 29(4):e70382.

PMID: 39993966 PMC: 11850087. DOI: 10.1111/jcmm.70382.

New insights in the pathogenesis of alcohol-related liver disease: The metabolic, immunologic, and neurologic pathways.

Ryu T, Kim K, Choi S, Chung K, Jeong W Liver Res. 2025; 7(1):1-8.

PMID: 39959703 PMC: 11791844. DOI: 10.1016/j.livres.2022.09.004.

Cell-to-cell and organ-to-organ crosstalk in the pathogenesis of alcohol-associated liver disease.

Gao H, Jiang Y, Zeng G, Huda N, Thoudam T, Yang Z eGastroenterology. 2024; 2(4).

PMID: 39735421 PMC: 11674000. DOI: 10.1136/egastro-2024-100104.

Emerging role of exosomes during the pathogenesis of viral hepatitis, non-alcoholic steatohepatitis and alcoholic hepatitis.

Shi C, Hu S, Liu S, Jia X, Feng Y Hum Cell. 2024; 38(1):26.

PMID: 39630211 DOI: 10.1007/s13577-024-01158-8.

References

Wang H, Gao B, Zakhari S, Nagy L . Inflammation in alcoholic liver disease. Annu Rev Nutr. 2012; 32:343-68. PMC: 3670145. DOI: 10.1146/annurev-nutr-072610-145138. View

Dubuquoy L, Louvet A, Lassailly G, Truant S, Boleslawski E, Artru F . Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut. 2015; 64(12):1949-60. PMC: 4558407. DOI: 10.1136/gutjnl-2014-308410. View

Natori S, Rust C, Stadheim L, Srinivasan A, Burgart L, Gores G . Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol. 2001; 34(2):248-53. DOI: 10.1016/s0168-8278(00)00089-1. View

Coleman M, Sahai E, Yeo M, Bosch M, Dewar A, Olson M . Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol. 2001; 3(4):339-45. DOI: 10.1038/35070009. View

Clemens D, Forman A, Jerrells T, Sorrell M, Tuma D . Relationship between acetaldehyde levels and cell survival in ethanol-metabolizing hepatoma cells. Hepatology. 2002; 35(5):1196-204. DOI: 10.1053/jhep.2002.32668. View

Henzel K, Thorborg C, Hofmann M, Zimmer G, Leuschner U . Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid. Biochim Biophys Acta. 2004; 1644(1):37-45. DOI: 10.1016/j.bbamcr.2003.10.017. View

Wu D, Cederbaum A . Ethanol cytotoxicity to a transfected HepG2 cell line expressing human cytochrome P4502E1. J Biol Chem. 1996; 271(39):23914-9. DOI: 10.1074/jbc.271.39.23914. View

Wu G, Burns T, Zhan Y, Alnemri E, El-Deiry W . Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 1999; 59(12):2770-5. View

Finnberg N, Gruber J, Fei P, Rudolph D, Bric A, Kim S . DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol. 2005; 25(5):2000-13. PMC: 549384. DOI: 10.1128/MCB.25.5.2000-2013.2005. View

10.

Feldstein A, Gores G . Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci. 2005; 10:3093-9. DOI: 10.2741/1765. View

11.

Mundt B, Wirth T, Zender L, Waltemathe M, Trautwein C, Manns M . Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut. 2005; 54(11):1590-6. PMC: 1774732. DOI: 10.1136/gut.2004.056929. View

12.

Schmitz V, Dombrowski F, Prieto J, Qian C, Diehl L, Knolle P . Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure. Hepatology. 2006; 44(2):430-9. DOI: 10.1002/hep.21274. View

13.

Chang J, Xie M, Shah V, Schneider M, Entman M, Wei L . Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc Natl Acad Sci U S A. 2006; 103(39):14495-500. PMC: 1599988. DOI: 10.1073/pnas.0601911103. View

14.

Malhi H, Barreyro F, Isomoto H, Bronk S, Gores G . Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut. 2007; 56(8):1124-31. PMC: 1955518. DOI: 10.1136/gut.2006.118059. View

15.

Pockros P, Schiff E, Shiffman M, McHutchison J, Gish R, Afdhal N . Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007; 46(2):324-9. DOI: 10.1002/hep.21664. View

16.

Thery C, Amigorena S, Raposo G, Clayton A . Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2008; Chapter 3:Unit 3.22. DOI: 10.1002/0471143030.cb0322s30. View

17.

Witek R, Stone W, Karaca F, Syn W, Pereira T, Agboola K . Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology. 2009; 50(5):1421-30. DOI: 10.1002/hep.23167. View

18.

Shiffman M, Pockros P, McHutchison J, Schiff E, Morris M, Burgess G . Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2010; 31(9):969-78. DOI: 10.1111/j.1365-2036.2010.04264.x. View

19.

Malhi H, Guicciardi M, Gores G . Hepatocyte death: a clear and present danger. Physiol Rev. 2010; 90(3):1165-94. PMC: 2943859. DOI: 10.1152/physrev.00061.2009. View

20.

Anstee Q, Concas D, Kudo H, Levene A, Pollard J, Charlton P . Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol. 2010; 53(3):542-50. DOI: 10.1016/j.jhep.2010.03.016. View